Rectal Cancer

P1/2, N=325, Completed, Bristol-Myers Squibb | Trial primary completion date: Mar 2024 --> Nov 2024

Elevated pre-CRT CEA levels and current smoking status were associated with a more than two fold increase in the risk of a higher TRG after NACRT. Moreover, smoking was a significant risk factor for poor OS in patients with LARC following NACRT.

We report that post-neoadjuvant modified Glasgow prognostic score associated with poorer response and regression, potentially indicating that radiation resistance is associated with the development of a protumor inflammatory environment. Further work is required to define the local intratumoral processes associated with response and their inter-relationship with systemic parameters. Ultimately, there may be a rationale for testing anti-inflammatory strategies in combination with radiotherapy as an option for optimizing treatment response. See Video Abstract.

P2, N=33, Not yet recruiting, Sir Run Run Shaw Hospital

P=N/A, N=128, Recruiting, Shandong Cancer Hospital and Institute | Trial completion date: Dec 2025 --> Dec 2028

P=N/A, N=40, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting

AF1q is expressed in RC, especially after short-term radiation therapy. Here, AF1q may support tumor suppression, possibly through the involvement of the pro-apoptotic STAT1 axis. Further mechanistic evidence and investigation involving a larger patient cohort are needed to validate a radiation-induced, AF1q-driven tumor-suppressing effect, which may impact RC patient outcomes.

The results of this study indicate that preoperative MRI detection is of great importance for predicting the risk of postoperative recurrence in patients with RC. Monitoring these markers helps clinicians identify patients at high risk, allowing for more aggressive treatment and monitoring strategies to improve patient outcomes.

P2, N=116, Not yet recruiting, First Affiliated Hospital of Zhejiang University

P2, N=364, Recruiting, Kyungpook National University Hospital | Trial primary completion date: Dec 2024 --> Jun 2025

P1, N=48, Active, not recruiting, The First Affiliated Hospital with Nanjing Medical University

P=N/A, N=13, Recruiting, Royal Marsden NHS Foundation Trust

P=N/A, N=16, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase classification: P2 --> P=N/A

P1, N=24, Recruiting, Barbara Ann Karmanos Cancer Institute | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026

We developed and validated a robust combined model that integrates clinical variables, classical radiomics features, and sub-region radiomics features to accurately determine the MSI status of RC patients. We visualized the prediction process using SHAP, enabling more effective personalized treatment plans and ultimately improving RC patient survival rates.

P3, N=228, Not yet recruiting, Shandong Cancer Hospital and Institute

P2, N=102, Not yet recruiting, First Affiliated Hospital of Zhejiang University

The postoperative course of the patient was uneventful. In cases of SANT following a prior malignancy, splenectomy should be considered for both diagnostic and therapeutic purposes.

P1, N=9, Recruiting, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

P=N/A, N=15, Terminated, Washington University School of Medicine | N=23 --> 15 | Trial completion date: Jan 2026 --> Nov 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jul 2024; Slow enrollment

P1, N=22, Recruiting, Medical College of Wisconsin | Trial completion date: Jun 2026 --> Jan 2029 | Trial primary completion date: Jun 2025 --> Apr 2027

P2, N=38, Completed, Stanford University | Active, not recruiting --> Completed

P2, N=38, Completed, Asan Medical Center | Unknown status --> Completed

P=N/A, N=179, Not yet recruiting, IRCCS San Raffaele

P2, N=40, Recruiting, Memorial Sloan Kettering Cancer Center

This study identified a significant correlation between VHL gene expression and RC for the first time using patient tissues and TCGA data, suggesting that the VHL gene expression level could be a potential biomarker or candidate for the treatment of RC. Further studies are required to identify the molecular pathogenesis and clinical characteristics of VHL disease in RC.

P=N/A, N=2443, Completed, Jagiellonian University | Active, not recruiting --> Completed | N=5000 --> 2443

Identifying gas gangrene mortality factors is fundamental to standardize management. Our study was able to build on the small size of our series, but further prospective and large-scale studies are required.

Thus, combined intratumoral microbiome-immune profiling improves the prediction of response to nCRT. Correct identification of unresponsive patients and of bacteria promoting responsiveness might lead to innovative therapeutic approaches based on gut microbiota pre-conditioning to increase nCRT effectiveness in LARC.

P=N/A, N=20, Recruiting, Centre Hospitalier Universitaire Saint Pierre | Not yet recruiting --> Recruiting

P=N/A, N=50, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025

P2, N=46, Recruiting, Fudan University

S100A11 and TLR3, representative candidate genes, exhibited different expression patterns and biological functions. This study highlighted the significant potential of the Anoscore in predicting prognosis and guiding the selection of personalized therapeutic regimens for patients with GI cancers.

Our DL model showed a better predictive performance than other state-of-the-art DL methods. The superior performance demonstrates the potential of our work for predicting RCLM, suggesting its potential assistance in personalized treatment and follow-up plans.

P=N/A, N=8, Completed, Centre Hospitalier de Saint-Denis

P1, N=12, Completed, Goethe University | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Dec 2024

P=N/A, N=196, Enrolling by invitation, Qianfoshan Hospital

P1, N=2, Terminated, Mayo Clinic | Trial completion date: Jan 2025 --> Oct 2024 | Active, not recruiting --> Terminated; slow accrual

P=N/A, N=20, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Sep 2025

P1, N=36, Not yet recruiting, City of Hope Medical Center

P3, N=68, Recruiting, Centre Hospitalier Universitaire Dijon | Not yet recruiting --> Recruiting | Trial completion date: Dec 2030 --> Sep 2030 | Trial primary completion date: Dec 2030 --> Sep 2030

P=N/A, N=264, Recruiting, University Hospital Tuebingen